Investor Presentaiton

TCB008 in vitro Safety Testing TC BIOPHARM • Furthermore, as TCB008 is a systemic infusion, the safety of TCB008 was further confirmed against representative healthy tissues from human skin, kidneys and lung As with the myeloid cells TCB008 was not cytotoxic against healthy human tissues at effector: target doses that exhibited potent cytotoxicity against cancer cells. These in vitro data are indicative that TCB008 is effective against AML cells whilst maintaining a suitable safety profile. T98G THP-1 H NHDF HREC HPMEC H HUVEC 100 80- Cytolysis (%) 60. TCB008 Lot 1 40- 20- — TCB008 Lot 2 0 E TCB008 Lot 3 DEL THAT -20- -40 THP-1 - AML Cell Line 1:1 4:1 8:1 1:1 4:1 8:1 1:1 4:1 8:1 1:1 4:1 8:1 1:1 4:1 8:1 1:1 4:1 8:1 T98G Glioblastoma Cell Line E:T NHDF - Primary Normal Human Dermal Fibroblasts HREC - Primary Human Renal Epithelial Cells HPMEC - Primary Human Pulmonary Microvascular Endothelial Cells HUVEC - Human Umbilical Vein Endothelial Cells (Cell Line) 9

View entire presentation